Abstract
Health-related quality of life (HRQoL) is important to consider in maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) as patients have minimal disease burden post ASCT. The phase 3, double-blind TOURMALINE-MM3 study demonstrated improved progression-free survival with ixazomib maintenance vs placebo post ASCT (Dimopoulos et al, Lancet 2019) and is the first study to evaluate the impact of post-ASCT maintenance on HRQoL in NDMM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
